Neumora’s June 15, 2026 update turns the $NMRA story into a cleaner but more unforgiving special situation: the former lead depression asset has now failed across the Phase 3 KOASTAL program, the company is discontinuing navacaprant, cutting approximately 35% of its workforce and trying to preserve enough runway to prove whether the remaining neuroscience pipeline can still justify investor attention.

After the collapse of Relyvrio in ALS, Amylyx is rebuilding its equity story around avexitide, a GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, a serious complication after bariatric surgery with no FDA-approved therapy. The pivotal LUCIDITY Phase 3 readout is expected in Q3 2026.

A fresh biotech tape with three very different clinical and regulatory signals: durable endocrine data from MBX Biosciences, a Phase 3 oncology setback for Jazz Pharmaceuticals, and a platform-supportive STAT6 degrader update from Kymera Therapeutics.

A full Merlintrader research report on Cogent’s transition from late-stage precision-medicine developer to potential commercial biotech, with focus on bezuclastinib in systemic mastocytosis and GIST, the June 2026 EHA catalyst, dual 2026 PDUFA dates, management, ownership, balance sheet, dilution risk, and the bull/bear setup.

Disc Medicine has moved from regulatory disappointment to a defined late-2026 readout path. The FDA Type A meeting does not erase the Complete Response Letter, but it gives investors a clearer framework: APOLLO must deliver clinically and statistically, and if it does, bitopertin may still have a path toward a traditional approval decision around mid-2027.

RedHill Biopharma gained renewed attention after the FDA granted Rare Pediatric Disease designation to opaganib for neuroblastoma, adding a potential Priority Review Voucher angle. But the full RDHL story involves far more than a single designation. With limited cash, going-concern risk, Nasdaq compliance pressure, and a pipeline requiring external funding, this remains a high-risk, high-volatility catalyst watch demanding strict risk discipline.